Recombinant Biotinylated Human DNAM-1 / CD226 Protein, Fc, Avitag™, 25 µg

Background
DNAX accessory molecule 1 (DNAM-1), a single-pass type I membrane protein, is also known as CD226 antigen and platelet and T cell activation antigen 1 (PTA1), which contains 2 Ig-like C2-type (immunoglobulin-like) domains. DNAM-1 is a ~65 kDa glycoprotein expressed on the surface of natural killer cells, platelets, monocytes and a subset of T cells. DNAM-1 mediates cellular adhesion to other cells bearing its ligands, CD112 and CD155, and cross-linking DNAM-1 with antibodies causes cellular activation. Furthermore, DNAM-1 can interact with PVR and PVRL2.

Source
Recombinant Biotinylated Human DNAM-1, Fc,Avitag (DN1-H82F9) is expressed from human 293 cells (HEK293). It contains AA Glu 19 - Asn 247 (Accession # NP_006557).
Predicted N-terminus: Glu 19

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus, followed by a Avi tag (Avitag™).
The protein has a calculated MW of 54.4 kDa. The protein migrates as 66-100 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein Ratio
Passed as determined by the HABA assay / binding ELISA.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20^°C to -70^°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1)  "Preventing Surgery-Induced NK Cell Dysfunction Using Anti-TGF-β Immunotherapeutics"
Market, Tennakoon, Scaffidi et al
Int J Mol Sci (2022) 23 (23)
(2)  "The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer Patients"
Pawłowska, Skiba, Suszczyk et al
Cancers (Basel) (2022) 14 (23)
(3)  "Extracellular CIRP Induces Novel Nectin-2+ (CD112+) Neutrophils to Promote Th1 Differentiation in Sepsis"
Murata, Murao, Aziz et al
J Immunol (2022)
Showing 1-3 of 407 papers.